A carregar...
A Novel Chimeric Protein-based HIV-1 Fusion Inhibitor Targeting gp41 Glycoprotein with High Potency and Stability
T20 (enfuvirtide, Fuzeon) is the first generation HIV-1 fusion inhibitor approved for salvage therapy of HIV-1-infected patients refractory to current antiretroviral drugs. However, its application is limited by the high cost of peptide synthesis, rapid proteolysis, and poor efficacy against emergin...
Na minha lista:
| Formato: | Artigo |
|---|---|
| Idioma: | en |
| Publicado em: |
American Society for Biochemistry and Molecular Biology
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3151085/ https://ncbi.nlm.nih.gov/pubmed/21690094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M111.241992 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|